🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A phase 2 nonrandomized clinical trial published in JAMA Oncology evaluated Nivolumab + Ipilimumab in patients with advanced clear cell ovarian and endometrial cancers—both known for poor chemo response. 🔹 ORR: 54% (3 CR, 12 PR) 🔹 6-month PFS: 58% 🔹 All responses ongoing 🔹 35%

Top #GICancer Trials for Q2 2025, curated by LARVOL CLIN based on oncologist sentiment on X. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights |

Top #GUCancer Trials for Q2 2025, curated by LARVOL CLIN based on oncologist sentiment on X. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights |

Top Heme-Onc Trials for Q2 2025, curated by LARVOL CLIN based on oncologist sentiment on X. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Hematology #Oncology #CancerResearch #CancerData #OncologyInsights

Top #LungCancer Trials for Q2 2025, curated by LARVOL CLIN based on oncologist sentiment on X. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights |

Top #LungCancer Oncologists for Q2 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | Stephen V Liu, MD | Aakash Desai, MD, MPH, FASCO |

Top #BreastCancer Oncologists for Q2 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | Paolo Tarantino | Yakup Ergün |

Top #GICancer Oncologists for Q2 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | Erman Akkus | Arndt Vogel |

Top #GUCancer Oncologists for Q2 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | Toni Choueiri, MD | Yüksel Ürün |

Top Women Oncologists for Q2 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #CancerData #OncologyInsights | Sharlene Gill, MD, MPH, MBA, FASCO | Aya Mohamed | MSc, MD 🎗 |

Top Heme-Onc Oncologists for Q2 2025, curated by LARVOL CLIN. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Hematology #Oncology #CancerResearch #CancerData #OncologyInsights | Fadi Haddad, MD | Vincent Rajkumar

BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer globenewswire.com/news-release/2… #LARVOL #CancerResearch #Oncology #BreastCancer #ClinicalTrials #CancerData #OncologyInsights

🟣 Q2 2025 Outcome Dataset on LARVOL CLIN Explore data from 146,000+ oncology trials and insights across 35 major conferences — all in one place to support faster, smarter oncology development: clin.larvol.com #LARVOL #Oncology #CancerResearch #ClinicalTrials

Kazia Therapeutics Reports Early Efficacy Data from First Triple-Negative Breast Cancer Patient Receiving Paxalisib Combination Regimen achieving >50% Reduction in Circulating Tumor Cells in Phase 1b Trial prnewswire.com/news-releases/… Learn more about ACTRN12624001340527

AI vs. 𝕏 OncoBuzz: Top 10 GI Cancer Trials Presented At ESMO - Eur. Oncology Gastrointestinal (GI) Cancers Congress 2025 We asked three AI models to identify the top 10 GI cancer trials presented at ESMO GI 2025 and compared them with 𝕏 OncoBuzz. Key findings: - TALENTACE (TACE +

European Commission Approves TEVIMBRA® in Combination with Chemotherapy as a First-Line Treatment for Nasopharyngeal Carcinoma businesswire.com/news/home/2025… Learn more about RATIONALE-309 (NCT03924986) 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch #Oncology #ClinicalTrials

XTANDI® Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence investors.pfizer.com/Investors/News… Learn more about EMBARK (NCT02319837) 👉 clin.larvol.com/trial-detail/N… #LARVOL #CancerResearch

It was a pleasure collaborating with Dr. Mina Nikanjam and Dr. Razelle Kurzrock (Razelle Kurzrock, MD) on our recent Cancer Letters paper exploring Nectin-4 as a biomarker and therapeutic target. Read the full study here: sciencedirect.com/science/articl… #Larvol #PrecisionMedicine #Biomarkers

🟣 Most active cancer institutes on X in Q2 2025, based on oncologists' posts and views. Explore more about oncology conferences, top trials, and reactions from oncologists: clin.larvol.com #LARVOL #Oncology #CancerResearch #ClinicalTrials #OncologyInsights #CancerData

The CHALLENGE trial (ASCO NEJM) revived hope for exercise in colorectal cancer debate continues. Now, a new meta-analysis shows: Consistent or increasing physical activity over adulthood cuts all-cause and CVD death risk by up to 40%. Move for your life at any age! The BMJ